866-997-4948(US-Canada Toll Free)

Human Papillomavirus Associated Diseases - Pipeline Insights, 2017

Published By :

DelveInsight

Published Date : Jul 2017

Category :

Pharmaceutical

No. of Pages : 199 Pages

DelveInsights, Human Papillomavirus Associated Diseases (HPV-AD) - Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs and vaccines for this area. This report also provides information on the therapeutic development for the Human Papillomavirus (HPV) Associated Diseases. It further provides comparative analysis at various stages covering Phase III, Phase II, Phase I, IND, and Pre clinical; therapeutics assessment by monotherapy products, combination products, drug molecule type and vaccine type (live/non-live). It also features the dormant and discontinued products.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, news websites, government websites, trade journals, white papers, magazines, trade associations, books, industry portals, industry associations and available databases.
Introduction
Overview
Pipeline Therapeutics: HPV-AD Drugs
Comparative Analysis
Late Stage Drugs (Phase III)
Mid Stage Drugs (Phase II)
Early Stage Drugs (Phase I and IND)
Pre-clinical Drugs
Therapeutic Assessment: Active HPV-AD Drugs
Dormant Drugs
Discontinued Drugs
Pipeline Therapeutics: HPV-AD Vaccines
Late Stage Vaccines (Phase III)
Mid Stage Vaccines (Phase II)
Early Stage Vaccines (Phase I)
Pre-clinical Vaccines
Mid Stage Vaccines (Phase II)
Early Stage Vaccines
Pre-clinical Vaccines
Dormant Vaccines
Discontinued Products
Appendix
Methodology
Consulting Services
About DelveInsight
Contact Us
Disclaimer

List of Table

Table 1: Total Drugs for HPV-Associated Diseases
Table 2: Late Stage Drugs (Phase III
Table 3: Mid Stage Drugs (Phase II
Table 4: Early Stage Drugs (Phase I and IND
Table 5: Pre-clinical Drugs
Table 6: Assessment by Monotherapy Drugs
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Drugs
Table 12: Discontinued Drugs
Table 13: Total Vaccines for HPV-
Table 14: Late Stage Vaccines (Phase III)
Table 15: Mid Stage Vaccines (Phase II)
Table 16: Early Stage Vaccines (Phase I)
Table 17: Pre-clinical Vaccines
Table 18: Mid Stage Vaccines (Phase II)
Table 19: Early Stage Vaccines (Phase I)
Table 20: Pre-clinical Vaccines
Table 21: Assessment by Monotherapy Vaccines
Table 22: Assessment by Route of
Table 23: Assessment by Stage and Route of Administration
Table 24: Assessment by Live or Non-live Vaccines
Table 25: Assessment by Stage and Live or Non-live Vaccines
Table 26: Dormant Vaccines
Table 27: Discontinued Products

List of Chart

Figure 1: Structure of Human papilloma virus
Figure 2: Types of HPV genotypes causing Anogenital infections
Figure 3: Non-genital Warts
Figure 4: Non-genital Warts
Figure 5: HPV-AD Products by Indication and Development Status
Figure 6: HPV-AD Products by Stage and Indication
Figure 7: Total Drugs for HPV-Associated Diseases
Figure 8: Late Stage Drugs (Phase III)
Figure 9: Mid Stage Drugs (Phase II)
Figure 10: Early Stage Drugs (Phase I and IND)
Figure 11: Pre-clinical Drugs
Figure 12: Assessment by Monotherapy Drugs
Figure 13: Assessment by Route of Administration
Figure 14: Assessment by Stage and Route of Administration
Figure 15: Assessment by Molecule Type
Figure 16: Assessment by Stage and Molecule Type
Figure 17: Dormant Drugs
Figure 18: Discontinued Drugs
Figure 19: Total Vaccines for HPV-AD
Figure 20: Late Stage Vaccines (Phase III)
Figure 21: Mid Stage Vaccines (Phase II)
Figure 22: Early Stage Vaccines (Phase I)
Figure 23: Pre-clinical Vaccines
Figure 24: Mid Stage Vaccines (Phase II)
Figure 25: Early Stage Vaccines (Phase I)
Figure 26: Pre-clinical Vaccines
Figure 27: Assessment by Monotherapy Vaccines
Figure 28: Assessment by Route of Administration
Figure 29: Assessment by Stage and Route of Administration
Figure 30: Assessment by Live or Non-live Vaccines
Figure 31: Assessment by Stage and Live or Non-live Vaccines
Figure 32: Dormant Vaccines
Figure 33: Discontinued Products

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *